ArticlePloS one2025
Lactoferrin combined with Coenzyme Q10 ameliorate sarcopenia in an aging mouse model induced by D-galactose.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia is an age-related condition with a slow and prolonged decrease in muscular mass, strength, and function. As the population ages, the frequency of sarcopenia rises, and aggressive prevention methods and effective treatment options are in urgent need. Here, we explore the hypothesis that nutritional interventions can ameliorate skeletal muscle aging in mice affected by sarcopenia, and the aforementioned hypothesis was validated through histopathological characterization and behavioral experiments. The model group exhibited reduced muscle mass (Lean Mass, GAS Index), muscular strength (Maximum Limb Muscle Strength), and muscular function (Exhaustion Time, Inverted Grid Time), along with increased fat content and smaller myofiber size compared to the control group. Treatments with lactoferrin and CoQ10, both individually and in combination, enhanced muscle indices and facilitated muscle tissue regeneration, with the combined treatment showing the most significant improvement. Research further shows that Lactoferrin and CoQ10, whether administered alone or in combination, were discovered to restrain the progression of sarcopenia by inhibiting both protein metabolism and mitochondrial energy metabolism, and compared to groups treated with lactoferrin or CoQ10 alone, the combined treatment demonstrated varying degrees of improvement across all evaluated metrics, such as Lean Mass (2.273 ~ 5.365%), Fat Mass (-1.058 ~ -0.359%), GAS index (0.259 ~ 0.335%), Maximum Limb Muscle Strength (6.83 ~ 53.498 g), Inverted Grid Time (563 ~ 859 s), Exhaustion Time (386 ~ 468 s).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.